Eğitim

Uzmanlık Kaydı: 23/12/91, İç Hastalıkları

16/2/94, Tıbbi Onkoloji

Tıp Eğitimi: Hacettepe Üniversitesi Tıp Fakültesi, Ankara, Türkiye. 1981-1987

Tıp Yeterlilikleri: İç Hastalıkları Uzmanı Aralık 1991

Tıbbi Onkolog Şubat 1994

Tıbbi Onkoloji Yardımcı Doçenti (Ondokuz Mayıs Üniversitesi) Mart 1994

Tıbbi Onkoloji Doçenti Ekim (Ondokuz Mayıs Üniversitesi) 1994

Tıbbi Onkoloji Profesörü (Başkent Üniversitesi) Mart 2003

Mevcut Pozisyon:

Tıbbi Onkoloji Anabilim Dalı Başkanı (Başkent Üniversitesi), Türkiye. 2002

Tecrübeler

Öğretim üyeliğim boyunca düzenli olarak tıbbi onkoloji uzmanlık öğrencilerine, iç hastalıkları asistanlarına ve tıp fakültesi öğrencilerine eğitim verme süreçlerinde yer aldım.

Derslerimin konuları:

-Lenfomalar

-Meme Kanseri

-Akciğer Kanseri

-Kanser Önleme

-Kanser için erken teşhis

-Onkolojide acil durumlar

-Onkolojide paraneoplastik sendromlar

-Kanser hastalarında enfeksiyon sorunları

-Kötü haberi verme becerisi

-Kanserde yorgunluk

-Kanser hastalarının yaşam kalitesi

-Üst sulkus tümörleri

-Miyeloproliferatif bozukluklar

-Kanser tarama programı

-Tümör belirteçleri

-Onkolojide palyatif bakım

Araştırma ve İlgi Alanları

Kas-iskelet radyolojisi (omurga, koksidini, kemik ve eklem patolojisi, kalsifik tendinit)

Nöroradyoloji ve nörovasküler görüntüleme (serebral anevrizmalar, hemimegalensefali, MSS lenfoması, beyaz madde hiperintensiteleri)

Orbital ve oküler görüntüleme (Graves oftalmopatisi, orbital travma, orbital kitleler, lakrimal bez ölçümleri)

Vasküler görüntüleme ve karotis aterosklerozu, özellikle yüksek rakımda yaşayan yaşlı hastalarda

Girişimsel nöroradyoloji ve serebral anevrizmaların endovasküler tedavisi

Acil radyoloji ve travma görüntüleme (bebeklerde kafa travması, acil orbital travma)

Radyolojik biyobelirteçler ve kantitatif görüntüleme (karotis intima-media kalınlığı, BNP/BDNF, morfometrik analizler)

Radyolojide yapay zeka / karar destek sistemleri (örneğin, ChatGPT ile ACL MRI karar destek sistemi).

Seçilmiş yazıları

1. O. Ozyilkan, E. Baltali, G. Tekuzman, A. Kars, D. Fırat. “Comparison of Ceruloplasminand CA 15-3 in Monitoring the Clinical Course of Patients with Breast Cancer” European Journal of Medicine 1992; 1 : 318.

2. O. Ozyilkan, E. Unlü, G. Tekuzman, S. Ruacan, E Baltalı, D. Fırat. “Superior Vena Cava Syndrome:

Experience at the Hacettepe Medical Center” Annals of Saudi Medicine 1992; 12 : 587-588.

3. O. Ozyilkan, E. Baltalı, E. Özyılkan, G. Tekuzman, A. Kars, D. Fırat. “Evaluation of Ceruloplasmin Level in Women with Breast Disease : Preliminary Results” Acta Oncologica 1992 ; 31 ; 843-846.

4. O. Ozyilkan, A. Kars, N. Güler, G. Tekuzman, E. Baltalı, D. Fırat. “Intra pleural andI ntraperitoneal Palliative Treatment of Malignant Effusions with Mitoxantrone” Anti-Cancer Drugs 1993; 4 : 98-99.

5. O. Ozyilkan, G. Tekuzman, A. Kars, E. Özyilkan, E. Baltalı, D. Firat. “Efficacy of Cyclophosphamide, Epirubicin, and Etoposide Alternating with Cisplatin and Etoposide in the Treatment of Patients with Small Cell Lung Cancer” Journal of Chemotherapy 1993; Supplement1 ; 785.

6. E.N. Guler, G. Tekuzman, A. Kars, E. Baltalı, I.H. Gullu, I. Barista, O. Ozyilkan. “Mitomycin, Ifosfamide, and Cisplatin Combined Chemotherapy Regimen in theTreatment of Inoperable Non-Small Cell LungCancer : a Preliminary Report” Recent Advances in Chemotherapy 1993 : 839.

7. A. Topeli, O. Ozyilkan, E. Özyilkan, A. Kars, D. Fırat. “Prevalence of Hepatitis C, B and D Markers in Cancer in Cancer Patients in Turkey” EuropeanJournal of Clinical Microbiology a Infectious Diseases 1994; 13 : 38-40.

8. E. Ozyilkan, O. Ozyilkan, H. Telatar, D. Fırat. “Hepatitis Virus Markers in Turkish Patients with Hepatocellular Carcinoma” Cancer 1994; 73 : 2002-2003.

9. M. Turgut, E. Baltalı, I. Barista, I.H. Güllü, n. Güler, SA. Kars, G. Tekuzman, O. Ozyilkan, G. Akpek, D. Fırat. “CEF (Cyclophosphamide, Epirubicin, Fluorouracil) and CNF (Cyclophosphamide, Mitoxantrone, Fluorouracil) Chemotherapy Protocols in Stage IV BreastCarcinoma” Proceedings of the XVI International CancerCongress 1994; 1437-1440.

10. O. Ozyilkan, E. Özyılkan, F. Karagöz, Ş. Özdamar, B. Kandemir. “Hepatitis C Virus Infection and Angioimmunoblastic Lymphadenopathy” American Journal of Gastroenterology 98/6; 1995: 1829-1830.

11. ŞO Özdamar, E. Özyilkan, O. Ozyilkan, B. Kandemir. “The Correlation Cell Nuclear Antigen Expressions in Coloreotal Adenocarcinoma” Pathology International 1995; 45: 973-974.

12. O. Ozyilkan, E. Karaagaoglu, A. Topeli, A. Kars, E. Baltalı, G. Tekuzman, D. Dinçer. “A Questionnaire for the Assessment of Quality of Life in Cancer Patients in Turkey” Materia Medica Polona 1995; 27(4) : 153-156.

13. O. Ozyilkan, M. Aslan, E. Özyılkan. “Hepatitis B Virusand Hepatitis C Virus Infection in Turkish Patients with Hepatocellular Carcinoma” American Journal of Gastroenterology 1996; 7: 1479-1488.

14. O. Ozyilkan, E. Baltalı, G. Tekuzman, D. Fırat. ’The impact of diagnosis and treatment on the quality of life in breast cancer patients’ Neoplasma 1998; 44 (1): 50 - 52.

15. O. Ozyilkan, E. Baltalı, O. Özdemir, G. Tekuzman, Ş. Kirazlı, D. Fırat. ‘Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer’ Tumori 1998; 84: 343 - 346.

16. Ş. Yalçın, A. Kars, Y. Özışık, G. Tekuzman, O. Ozyilkan, İ. Çelik, İ. Barışta, İ. Güllü, N. Güler, E. Baltalı, D. Fırat. ‘VB – CHEP chemotherapy regimen for aggressive non-Hodgkin’slymphoma’ Am.. J. Clin. Oncol 1998; 61(4): 261-265.

17. I. Çelik, A. Kars, N. Güler, İ. Barışta, G. Tekuzman, O. Ozyilkan, M. Hayran, D. Fırat. ‘Phase II trial of MINE as a front-line therapeutic modality in intermediate and high grade non-Hodkgin’slymphoma’ Eur. J. Cancer 1998; 34(5): 759-760.

18. O. Ozyilkan, Ü. Yalçıntaş S. Başkan. ‘Imipenem-Cilastatin versus Sulbactam-Cefoperazone plus Amikacin in the Initial Treatment of Febrile Neutropenic Cancer Patients’ The Korean Journal of Internal Medicine1999: 14(2): 15-19.

19. O. Ozyilkan, E. Özyılkan. ‘Gastric Hodgkin’s Disease Presenting with Radiologic Appearance of Linitis Plastica’ American Journal of Gastroenterology1999; 12: 3661-3662.

20. O. Ozyilkan, E. Baltali, S. Kirazli ’ A tumour marker panel: CA 15-3, ceruloplasmin and tissue polypeptide specific antigen in breast cancer’ East AfricanMedical Journal 2000, 77; 36-39.

21. Z. Aki, G. Kotiloglu, O. Ozyilkan ‘A patient with a prolonged prothrombin time due to an adverse interation between 5-Fluorouracil and warfarin’ American Journal of Gastroenterology 2000; 950: 1093-1094.

22. G. Kotiloglu, Z. Aki, O. Ozyilkan , L. Kutlay, ‘Tamoxifen induced cirrhotic proces’, The Breast Journal, 2001,7(6): 442 - 443.

23. L. Filik, S. B. Hizel, C. Gündoğdu, N. Ozgirgin, O. Ozyilkan, “Lung cancer detected early in a patient after treatment of laryngeal cancer”. Journal of Balkan Union of Oncology. 2001, 6: 449 - 450

24, G. Kotiloglu, O. Ozyilkan, “Vinorelbine in elderly patients with in operable non small cell lung carcinoma” Cancer, 2002. 1,94(1): 282-283.

25. L. Filik, O. Ozyilkan. “Adenocarcinoma of the Lung in a 32- Year-Old Man: Is it Worthwhile to Check forLung Cancer in YoungAdults”. Onkologie, 2002, 25: 64-65

26. L. Filik, T. Oskay, O. Ozyilkan. “Conjunctival Involvement in a Patient with Cutaneous Malignant Melanoma”. Onkologie, 2002, 25: 65-65

27. L. Filik, O. Ozyilkan “A Man who has been Smoking Since He was 12-month-old” Journal of Balkan Union of Oncology, 2002, 7, 427-428s

28. Z. Akcali, E. Akin, O. Ozyilkan “Factors Predicting Response and Survival in 149 Patients with Unresectable Hepatocellular Carcinoma Treated by Combination Cisplatin, Interferon-alpha, Doxorubicin, and 5-fluorouracil Chemotherapy” Cancer, 2002,95, 2038-2039.

29. S. Saglam, B. Yetiş, O. Ozyilkan, Z. Akçalı. “Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best SupportiveCare as Second-LineTherapy of Advanced Non-Small- Cell Lung Cancer” Journal of Clinical Oncology, 2002, 20, 3750-3751.

30. T. Oskay, L. Kutluay, O. Ozyilkan. “Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycytemiavera” European J ournal of Dermatology, 2002, 12(6) 586 –588.

31. L. Filik, O. Ozyilkan. “Olive Oil and Cancer Risk” European Journal of Clinical Nutrition, 2003, 57,191.

32.Akcali Z, Ozyilkan O, Moray G, Emiroglu R, Haberal M, ‘Treatment Results in Renal Transplant Recipients with Non-Hodgkin's Lymphoma’ Transplantation Proceedings, 35/4, 1404-1407, 2003

33. Karakus S, Akcali Z, Ozyilkan O, Demirhan B, Haberal M. ‚’Acute Myeloid Leukemai 4 Years After Kaposi in a Renal Transplant Recipient: Case report’, Onkologie, 27(2):163-5, 2004

34. L. Filik, S. Ozdal-Kuran, B. Cicek, N. Zengin, O. Ozyilkan , ‘Appendicular metastasis from pancreatic adenocarcinoma’ Int J Gastrointest Cancer. 34(1):55-8. 2004.

35. Z. Akcali, H. Sakalli, O. Ozyilkan, T. Noyan. ‘MALTOMA Presenting with Thrombocytopenia’ American Journal of Clinical Oncology 2005 Jun;28(3):321-2.

36. Z. Akcali, H. Sakalli, O. Ozyilkan, T. Noyan ‘Primary Thyroid Lymphoma: Report of Two Cases’ East African Medical Journal, 2004 Jul;81(7):378-80.

37. Karacan O, Eyuboglu FO, Akcay S, Ozyilkan O. Acuteinterstitial pneumopathy associated with docetaxel hypersensitivity.Onkologie. 2004 Dec;27(6):563-5.

38. Cakir B, Tarhan NC, Coskun M, Ozdemir BH, Bozkurt A, Ozyilkan O., Metastatic Cerebellar Medulloblastoma in theLiver Mimicking a Complicated Cyst: Sonographicand MDCT Findings., AJR Am J Roentgenol. 2004 Dec;183(6):1608-10.

39. O. Ozyilkan, D. Colak, Z. Akcali, B. Basturk. ‘Olive: Fruit of Peace Against Cancer’ Asian Pacific J Cancer Prevent. 2005 Jan-Mar;6(1):77-82.

40. Akcali Z, Sakalli H, Ozyilkan O, Demirhan B, Haberal M. Prognostically favorable abdominal breast cancer metastases with stomach involvement. Onkologie. 2005 May;28(5):270-2.

41. Yildirim Y, Akcali Z, Ozyilkan O.Controversy in folinicacidadministrationafterfluorouracil. J ClinOncol. 2005 Jun 1;23(16):3862; authorreply 3862-3.

42.Ulubay G, Eyuboglu FO, Simsek A, Ozyilkan O.Multiple myeloma with pleural involvement: a case report. Am J Clin Oncol. 2005 Aug;28(4):429-30.

43. Colak D, Ozyilkan O,Akcali Z, Bilezikci B. Hodgkin'sdisease in an elderly patient with B-Cell chronic lymphocytic leukemia. Indian J Cancer. 2005 Jul-Sep;42(3):158-60.

44. Akcali Z, Ozyilkan O, Sakalli H, Bal N, Noyan T.’ Primary squamous cell carcinoma of the stomach: a case report’. Tumori. 2005 Sep-Oct;91(5):440-2.

45. Yildirim Y, Ozyilkan O, Akcali Z, Basturk B. Drug interaction between capecitabine and warfarin: a case report and review of the literature. Int J Clin Pharmacol Ther. 2006 Feb;44(2):80-2.

46. Yildirim Y, Ozyilkan O, Emiroglu R, Demirhan B, Karakayali H, Haberal M.’ Early diagnosis of cancer in renal transplant patients: a single center experience.’ Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):336-9.

47. Topkan E, Yavuz AA, Ozyilkan O. ‘Cancercachexia: pathophysiologic aspects and treatment options.’ Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):445-51.

48. Ertorer ME, Tutuncu NB, Ozyilkan O. ‘Incidental papillary microcarcinoma of the thyroid.’ Asian Pac J Cancer Prev. 2007 Oct-Dec;8(4):631-4.

49. Yildirim Y, Akca Y, Ozyilkan O, Celasun B. ‘Prostate small cell carcinoma and skin metastases: a rare entity’ Med Princ Pract. 2008;17(3):250-2.

50. Murat Sedef A, Kose F, Taner Sumbul A, Dogan O, Kursun E, Yurdakul Z, Sumbul Gultepe B, Mertsoylu H, Sezer A, Ozyilkan O. Prognostic value of procalcitonin in infection-relatedmortality of cancer patients. J BUON. 2016 May-Jun;21(3):740-4.

51. Sümbül AT, Sezer A, Abali H, Gültepe B, Koçer E, Reyhan M, Tonyalı Ö, Özyilkan Ö.

An old enemy not to be forgotten during PET CT scanning of cancer patients: tuberculosis.Contemp Oncol (Pozn). 2016;20(2):188-91

52.Kose F, Findikcioglu A, Canpolat T, Sedef AM, Besen A, Mertsoylu H, Ozyilkan O, Abali H.

Predictive and prognostic role of T-regulatorycells in resectednon-smallcell lung cancer. J Thorac Oncol. 2016 Apr;11(4 Suppl):S103-4.

53. Onal C, Oymak E, Reyhan M, Canpolat T, Ozyilkan O. Multifocal soft tissue Langerhans' cell histiocytosis treated with PET-CT based conformal radiotherapy. Jpn J Radiol. 2015 Sep;33(9):603-6. doi: 10.1007/s11604-015-0466

54.Sedef AM, Kose F, Mertsoylu H, Ozyilkan O. Procalcitonin as a biomarker for infection-related mortality in cancer patients.Curr Opin Support Palliat Care. 2015

55. Aykan NF, Yalçın S, Turhal NS, Özdoğan M, Demir G, Özkan M, Yaren A, Camcı C, Akbulut H, Artaç M, Meydan N, Uygun K, Işıkdoğan A, Ünsal D, Özyılkan Ö, Arıcan A, Seyrek E, Tekin SB, Manavoğlu O, Özet A, Elkıran T, Dişçi Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Grouptrial). . Turk J Gastroenterol. 2015 Mar;26(2):145-53. doi: 10.5152/tjg.2015.5685.

56. Sedef AM, Köse F, Doğan Ö, Ergün T, Sezer A, Mertsoylu H, Muallaoğlu S, Beşen A, Özyilkan Ö. Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases.Mol Clin Oncol. 2015 Mar;3(2):400-402.

57. Tanriverdi O, Cay-Senler F, Yavuzsen T, Turhal S, Akman T, Komurcu S, Cehreli R, Ozyilkan O. The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and PalliativeCare (ALONE Study): A Study of thePalliative Care Working Committee of theTurkish Oncology Group (TOG).Med Oncol. 2015 Apr;32(4):106

58. Mertsoylu H, Köse F, Sümbül AT, Sedef AM, Doğan Ö, Besen AA, Parlak C, Fındıkçıoğlu A, Muallaoğlu S, Sezer A, Sakallı H, Özyılkan Ö. .Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience. Asian Pac J Cancer Prev. 2014;15(17):7207-11.

59. Sezer A, Sümbül AT, Abali H, Mertsoylu H, Muallaoğlu S, Köse F, Ozyilkan O. Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience. Hepatogastroenterology. 2014 Oct;61(135):1895-900.

.60.Tanriverdi O, Yavuzsen T, Akman T, Senler FC, Taskoylu BY, Turhal S, Komurcu S, Cehreli R, Yaren A, Ozyilkan O. The Perspective of Non-oncologist Physicians on Patients with Metastatic Cancer and Palliative Care (ALONE Study): A Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). 0J CancerEduc. 2015 Jun;30(2):253-9. doi: 10.1007/s13187-015-0794-3.

61.Sedef AM, Köse F, Sümbül AT, Doğan Ö, Beşen AA, Tatlı AM, Mertsoylu H, Sezer A, Muallaoğlu S, Özyılkan Ö, Abalı H. Patients with distal intestinal gastric cancer have superior out come with addition of taxane stocombination chemotherapy, while proxima lintestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?

Med Oncol. 2015 Feb;32(2):476.

62.Türker İ, Kömürcü Ş, Arıcan A, Doruk H, Özyılkan Ö, Coşkun HŞ, Colak D, Üçgül Çavuşoğlu E, Ata A, Sezer A, Yeşil Çınkır H, Şenler FC, Arpacı F. Investigational tests and treatments per formed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study.

Med Oncol. 2014 Dec;31(12):350. doi: 10.1007/s12032-014-0350-8.

63.Sumbul AT, Sezer A, Abali H, Dicel U, Gultepe I, Besen AA, Ozyilkan O.

Continuous distress in an oncology clinic in Turkey: should we make use of the distress the rmometer mandatory as a precautionary measure for physicians? J BUON. 2014 Jul-Sep;19(3):807-11.

64.Mertsoylu H, Muallaoglu S, Besen AA, Erdogdu S, Sezer A, Sedef AM, Kose F, Arican A, Ozyilkan O. Primary extranodal non-Hodgkin'slymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey.Asian Pac J Cancer Prev. 2014;15(17):7207-11.

65.Taner Sumbul A, Sezer A, Tonyali O, Akif Ozturk M, Abali H, Ozyilkan

Being a medical oncologist near the war area. J BUON. 2014 Apr-Jun;19(2):580.

66.Muallaoglu S, Disel U, Tekin A, Mertsoylu H, Abali H, Ozyilkan O.

.Prolonged use of bevacizumab may cause extensive coronary artery thrombosis. J BUON. 2014 Apr-Jun;19(2):578-9

67.Karadeniz C, Mertsoylu H, Ayberk Besen A, Sezer A, Murat Sedef A, Kose F, Ozyilkan O. The clinicopathological and survival differences between never and ever smokers withnon-small cel llung cancer. J BUON. 2014 Apr-Jun;19(2):453-8.

68.Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Ozyılkan O. Malignant pleural mesothelioma: a single-center experience in Turkey. Med Sci Monit. 2014 May 20;20:825-32..

69. Sümbül AT, Dişel U, Sezgin N, Sezer A, Köse F, Beşen AA, Sümbül Z, Abalı H, Özyılkan Ö

Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment? Med Sci Monit. 2014 Mar 15;20:428-33

70.Muallaoglu S, Besen AA, Ata A, Mertsoylu H, Arican A, Kayaselcuk F, Ozyilkan O. ck of prognostic significance of C-erbB-2 expression in low- and high- grade as trocytomas.

AsianPac J CancerPrev. 2014;15(3):1333-7.

71.Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, Muallaoğlu S, Özyılkan Ö.

Neutrophil-to-lymphocyt era tiopredicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Uro lNephrol. 2014 Aug;46(8):1531-5.

72.Kuzan TY, Koca E, Dizdar O, Arslan C, Eren T, Yalcin S, Kucukoztas N, Aksoy S, Rahatli S, Dede DS, Altundag O, Zengin N, Ozyilkan Breast cancer in octogenarian women: clinica lcharacteristics and outcome. J BUON. 2013 Apr-Jun;18(2):328-34.

73.Muallaoglu S, Disel U, Mertsoylu H, Besen A, Karadeniz C, Taner Sumbul A, Abali H, Ozyilkan O.Acute infusion reactions to chemotherapeutic drugs: a single institute experience. J BUON. 2013 Jan-Mar;18(1):261-7.

74.Abali H, Sezer A, Oğuzkurt L, Gürel K, Özkan U, Beşen AA, Sümbül AT, Köse F, Dişel U, Muallaoğlu S, Özyılkan Ö. h patients with advanced cancer and biliary obstruction benefit from biliary stentingmost? An analysis of prognosticfactors.SupportCareCancer. 2013 Apr;21(4):1131-5

75. Sumbul AT, Kose F, Oğuzkurt L, Karadeniz C, Kocer NE, Ozyilkan O.Successful treatment of aortic rupture withend ovascular stent grafting in a patient with mantle cell lymphoma. Case Rep Oncol. 2012 May;5(2):275-9.

76. Dişel U, Beşen A, Karadeniz C, Mertsoylu H, Sezer A, Köse F, TanerSümbül A, Gürkut O, Muallaoğlu S, Abali H, Ozyilkan .Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study.Med Oncol. 2012 Dec;29(5):3608-13.

77. Dişel U, Abalı H, Sümbül AT, Ozyılkan O. Hypertension associated with angiogoenesis inhibitors: what do oncologists really do in daily routine? A small survey. J Clin Hypertens (Greenwich). 2011 Nov;13(11):863.

78.Kose F, Besen A, Sumbul T, Sezer A, Karadeniz C, Disel U, Altundag O, Ozyilkan

Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience. AsianPac J CancerPrev. 2011;12(5):1185-8.

79. Dişel U, Beşen AA, Özyılkan Ö, Er E, Canpolat T. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol. 2012 Feb;48(2):e2-3.

80.Kose F, Oguzkurt L, Besen A, Sumbul T, Sezer A, Karadeniz C, Disel U, Mertsoylu H, Ozyilkan O. Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience.Eur J Radiol. 2012 Aug;81(8):1724-7.

81. Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal GN, Abalı H, Ozyılkan. Promising efficacy of sorafenib in a relapsed thymic carcinomawith C-KIT exon 11 deletion mutation. LungCancer. 2011 Jan;71(1):109-12.

82. ChernyNI; Factor sinfluencing the attitude sand behaviors of oncologists regarding the truthful disclosure of informationto patients with advanced and incurable cancer.

Cherny NI; Palliative CareWorking Group of the European SocietyforMedicalOncology..

Psychooncology. 2011 Dec;20(12):1269-84.

83. Yildirim Y, Akcali Z, Ozyilkan O. Signet-ring cell carcinoma of the colon with leptomeningeal involvement.Rapidly progressing malignant insulinoma presented with multiple liver metastases: a case report. J ClinNeurosci. 2010 Aug;17(8):1051-3

84. Erdogan A, Kose F, Akkaya H, BascilTutuncu N, Ozyilkan O. Rapidly progressing malignant insulinoma presented with multiple liver metastases: a case report.. J GastrointestCancer. 2010 ec;41(4):272-4.

85. Disel U, Gürkut O, Abali H, Kaleağasi H, Mertsoylu H, Ozyilkan O, Saif MW. Unilateral hand-footsyndrome: an extra ordinary side effect of capecitabine.Cutan Ocul Toxicol. 2010 Jun;29(2):140-2

86.Yildirim Y, Ozyilkan O, Calikusu Z, Akcali Z, Akcay Y, Demirhan B. Management of elderly patients with advanced non-small cell lung cancer in Turkey.AsianPac J CancerPrev. 2009 Oct-Dec;10(4):699-700.

87.Calikusu Z, Yildirim Y, Akcali Z, Sakalli H, Bal N, Ozyilkan O. Prognostic significance of the C-erbB-2 expression in turkish non-small cell lung cancer patients. AsianPac J CancerPrev. 2009 Jul-Sep;10(3):479-82.

88. Calikusu Z, Yildirim Y, Akcali Z, Sakalli H, Bal N, Unal I, Ozyilkan O. The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. J Exp Clin Cancer Res. 2009 Jul 3;28:97

89. Kose F, Sakalli H, Mertsoylu H, Sezer A, Kocer E, Tokmak N, Kilinc F, Ozyilkan O.

Primaryrenallymphoma: report of fourcases.  Colon adenocarcinoma and solitary tibia metastasis: rare entity.Onkologie. 2009 Apr;32(4):200-2

90.Kose F, Abali H, Sezer A, Mertsoylu H, Disel U, Ozyilkan O. Little dose, huge toxicity: profound hematological toxicity of intra thecal methotrexate.LeukLymphoma. 2009 Feb;50(2):282-3

91.Akcali Z, Calikusu Z, Sakalli H, Ozyilkan O.Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.Tumori. 2008 Jul-Aug;94(4):474-80.

92.Yildirim Y, Ozyilkan O, Bilezikci B, Akcali Z, Haberal M. Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival.Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):295-8.

93 .Kose F, Bal N, Ozyilkan O. Squamous cell carcinoma of the renal pelvis.Med Oncol. 2009;26(1):103-4.

94.Karabulut Z, Yildirim Y, Abaci I, Ilgici D, Ozyilkan O. Signet-ring cell carcinoma of the gallbladder: a case report. AdvTher. 2008 May;25(5):520-3.

Murat Sedef A, Kose F, Taner Sumbul A, Dogan O, Kursun E, Yurdakul Z, SumbulGultepe B, Mertsoylu H, Sezer A, Ozyilkan O.Prognostic value of procalcitonin in infection-related mortality of cancer patients.J BUON. 2016 May-Jun;21(3):740-4.

96. Sümbül AT, Sezer A, Abali H, Gültepe B, Koçer E, Reyhan M, Tonyalı Ö, Özyilkan Ö. An old enemy not to be forgotten during PET CT scanning of cancer patients: tuberculosis.Contemp Oncol (Pozn). 2016;20(2):188-91.

97.. Kose F, Findikcioglu A, Canpolat T, Sedef AM, Besen A, Mertsoylu H, Ozyilkan O, Abali H. 110P: Predictive and prognostic role of T-regulatory cells in resected non-smallcell lung cancer.

J ThoracOncol. 2016 Apr;11(4 Suppl):S103-4. doi: 10.1016/S1556-0864(16)30223-4. Epub 2016 Apr 15. No abstractavailable.

98. Onal C, Oymak E, Reyhan M, Canpolat T, Ozyilkan O.Multifocal soft tissue Langerhans' cell histiocytosis treated with PET-CT based conformalradiotherapy .Jpn J Radiol. 2015 Sep;33(9):603-6.

99. Sedef AM, Kose F, Mertsoylu H, Ozyilkan O.Procalcitonin as a biomarker for infection-related mortality in cancer patients.Curr Opin Support PalliatCare. 2015 Jun;9(2):168-73..1

100. Aykan NF, Yalçın S, Turhal NS, Özdoğan M, Demir G, Özkan M, Yaren A, Camcı C, Akbulut H, Artaç M, Meydan N, Uygun K, Işıkdoğan A, Ünsal D, Özyılkan Ö, Arıcan A, Seyrek E, Tekin SB, Manavoğlu O, Özet A, Elkıran T, Dişçi R.Epidemiology of colorectalcancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Grouptrial).Turk J Gastroenterol. 2015 Mar;26(2):145-53.

101. Sedef AM, Köse F, Doğan Ö, Ergün T, Sezer A, Mertsoylu H, Muallaoğlu S, Beşen A, Özyilkan Ö. Targeted treatment with pazopanib in metastatic soft tissue sarcoma: Nearly complete response in two cases.Mol Clin Oncol. 2015 Mar;3(2):400-402. Epub 2014 Nov 13.

102. Tanriverdi O, Cay-Senler F, Yavuzsen T, Turhal S, Akman T, Komurcu S, Cehreli R, Ozyilkan O.Perspectives and practical applications of medical oncologists on defensive medicine (SYSIPHUS study): a study of the Palliative Care Working Committee of theTurkish Oncology Group (TOG).MedOncol. 2015 Apr;32(4):106.

103. Mertsoylu H, Köse F, Sümbül AT, Sedef AM, Doğan Ö, Besen AA, Parlak C, Fındıkçıoğlu A, Muallaoğlu S, Sezer A, Sakallı H, Özyılkan Ö. Concurrent chemoradiotherapywith vinorelbine plussplit-dose cisplatin may be an option in inoperablestage III non-smallcelllungcancer: a single-center experience.MedSciMonit. 2015 Mar 3;21:661-6.

104. Yalçın Ş, Yildiz R, Dane F, Karaoğlu A, Öksüzoğlu B, Özyılkan Ö, Sevinç A, Özdemir F, Turna H, Uslu R, Ulay E.A national, multi center, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study.

OncoTargetsTher. 2018 Mar 5;11:1223-1228.

105 Topkan E, Selek U, Ozdemir Y, Yildirim BA, Guler OC, Ciner F, Besen AA, Findikcioglu A, Ozyilkan O. Incidence and Impact of Pretreatment Tumor Cavitation on Survival Outcomes of Stage III Squamous Cell Lung Cancer Patients Treated With Radical Concurrent ChemoradiationTherapy.Int J RadiatOncolBiolPhys. 2018 Aug 1;101(5):1123-1132.

106. Oktay E, Levent M, Gelincik H, Aktaş G, Yumuk F, Koral L, Arpacı E, Keser M, Alkan A, Karci E, Karadurmuş N, Degirmencioglu S, Turan M, Uyeturk U, Cabuk D, Avci N, Toprak O, Ergen A, Urvay S, Bayman E, Petekkaya E, Nayir E, Paydaş S, Yavuzsen T, Senler FC, Yaren A, Barutca S, Şahinler İ, Ozyilkan O, TanriverdiO. Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, PalliativeCare, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of theTurkish Oncology Group (TOG).J CancerEduc. 2018 Nov 16. doi: 10.1007/s13187-018

107. Topkan E, Selek U, Ozdemir Y, Besen AA, Guler OC, Yildirim BA, Mertsoylu H, Findikcioglu A, Ozyilkan O, Pehlivan B. Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell LungCarcinomaPatients. J Oncol. 2018 Nov 1;2018:4518935.

108. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-celllung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.Lancet. 2019 May 4;393(10183):1819-1830.

109. Murat Sedef A, Taner Sumbul FKA, Ayberk Besen A, Hacioglu B, Gunaldi M, Nayir E, Tanriverdi O, Arpaci E, Abali H, Ozyilkan O. Addition of taxanes to combination chemotherapy in distal intestinal gastric cancer is more beneficial than proximalones: A multicenter retrospective study of Turkish Oncology Group.J BUON. 2019 Mar-Apr;24(2):650-655.

110. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators.Pembrolizumab for EarlyTriple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810-821.

111. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, WanIshak WZ, Hong RL, GonzálezMendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrentormet a static squamouscell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.Lancet. 2019 Nov 23;394(10212):1915-1928. Clinical Trial.

112. Nakagawa K, Garon EB, Seto T, Nishio M, PonceAix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY StudyInvestigators.Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lungcancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetOncol. 2019 Dec;20(12):1655-1669. Clinical Trial.

113. Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, duToit Y, Easton V, Lindegger N, Miles D; PERUSE investigators.Preliminary safetyandefficacy of first-line pertuzumab combined with trastuzumab and taxane therapyfor HER2-positive locally recurrent or metastatic breastcancer (PERUSE).AnnOncol. 2019 May 1;30(5):766-773.. Clinical Trial.

114. Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Chapman SC, Lu Y, Hardebeck MC, Bear MM, Johnston EL, Martin M.

nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.Clin BreastCancer. 2021 Jun;21(3):181-190.e2. d

115. Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC.GLASS: Global Lorlatinibfor ALK(+) and ROS1(+) retrospectiveStudy: realworld data of 123 NSCLC patients. Lung Cancer. 2020 Oct;148:48-54.

116. Acibuca A, Sezer A, Yilmaz M, Sumbul AT, Demircan S, Muderrisoglu IH, Ozyilkan O.J Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-centerexperience. Int Med Res. 2021 Dec;49(12):3000605211053755. doi: 10.1177/03000605211053755.

117. Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S.J Tyrosinekinaseinhibitors in thetreatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.Oncol PharmPract. 2021 Oct;27(7):1623-1630. doi: 10.1177/1078155220963535. Epub 2020 Oct 13.PMID: 33050804

118. Akarca US, Unsal B, Sezgin O, Yalcin K, Akdogan M, Gonen C, Gunduz F, Ozenirler S, Sonsuz A, Dincer D, Tekin SB, Yucel I, Akbulut H, Alkım C, Ozyilkan O, Baygul A, Cevik ZM, Idilman R, StudyGroupOBOKRCharacteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K RegistryStudy..Turk J Gastroenterol. 2021 Dec;32(12):1019-1028. doi: 10.5152/tjg.2021.201171.PMID: 34876392

119. Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breastcancer in a real-world setting: phase IIIb LUCY interimanalysis.

Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1.PMID: 34087573 Clinical Trial.

120. Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, MoralesBarrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, HometMoreno B, Alva A; KEYNOTE-361 Investigators  Freearticle. Clinical Trial. Pembrolizumab alone or combined with chemotherapy versuschemotherapy as first-linet herapy for advancedurothelialcarcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. LancetOncol. 2021 Jul;22(7):931-945. doi: 10.1016/S1470-2045(21)00152-2. Epub 2021 May 26.PMID: 34051178 Clinical Trial.

121. ShitaraK  ·Doi T, Hosaka H  · Thuss‑Patience P , Santoro A· Longo F · Ozyilkan O  · Cicin I  · Park P  · Zaanan A,  · Pericay C,  · Özgüroğlu M,  · Alsina M · Makris L · Benhadji KA,  ·  Ilson DH Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophagealjuncion cancer: subgroup analysis of a randomized phase 3 study (TAGS) GastricCancer, 2022 https://doi.org/10.1007/s10120-021-01271-9

122. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.

.N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.PMID: 35139274

123. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators.N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809.PMID: 35857659

124. Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Zhang W, Chen Y, Martin M nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.

.Breast Cancer Res Treat. 2022 Aug;195(1):55-64. doi: 10.1007/s10549-022-06662-9. Epub 2022 Jul 12.PMID: 35829935

125. Sedef AK, Yildirim BA, Sumbul AT, Ozyilkan O. Thoracic Radiotherapy Effect on the Outcome in Extensive Stage Small Cell Lung Cancer. J Coll Physicians Surg Pak. 2023 Feb;33(2):188-192. doi: 10.29271/jcpsp.2023.02.188.PMID: 36797629

126. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr

127. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.

Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators.N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.PMID: 38598794 Clinical Trial.

128 Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, Hayashi H; MARIPOSA Investigators.N Engl J Med. 2024 Oct 24;391(16):1486-1498. doi: 10.1056/NEJMoa2403614. Epub 2024 Jun 26.PMID: 38924756 Clinical Trial.

129.SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.

Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M.J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.PMID: 37976444 Free PMC article. Clinical Trial.

130.Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.

Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators.J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.PMID: 38857463 Free PMC article. Clinical Trial.

131. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.

Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators.Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29.PMID: 38561010 Clinical Trial.

132.Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.

Balmaña J, Fasching PA, Couch FJ, Delaloge S, Labidi-Galy I, O'Shaughnessy J, Park YH, Eisen AF, You B, Bourgeois H, Gonçalves A, Kemp Z, Swampillai A, Jankowski T, Sohn JH, Poddubskaya E, Mukhametshina G, Aksoy S, Timcheva CV, Park-Simon TW, Antón-Torres A, John E, Baria K, Gibson I, Gelmon KA; LUCY investigators.Breast Cancer Res Treat. 2024 Apr;204(2):237-248. doi: 10.1007/s10549-023-07165-x. Epub 2023 Dec 19.PMID: 38112922 Free PMC article. Clinical Trial.

132. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.

Kuemmel S, Harper-Wynne C, Park YH, Franke F, de Laurentiis M, Schumacher-Wulf E, Eiger D, Heeson S, Cardona A, Özyilkan Ö, Morales-Vàsquez F, Metcalfe C, Hafner M, Restuccia E, O'Shaughnessy J.BMC Cancer. 2024 May 24;24(1):641. doi: 10.1186/s12885-024-12179-9.PMID: 38789924 Free PMC article. Clinical Trial.

133 Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non-Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy.

Hochmair M, Schenker M, Dols MC, Kim TM, Ozyilkan O, Smagina M, Viktoriya L, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E. J Thorac Oncol. 2024 Oct 28:S1556-0864(24)02420-1. doi: 10.1016/j.jtho.2024.10.012. Online ahead of print.PMID: 39477187

134 Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, García Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruíz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group.N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi: 10.1056/NEJMoa2410858. Epub 2024 Dec 11.PMID: 39660834 Clinical Trial.

135 . Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy.

Hochmair M, Schenker M, Cobo Dols M, Kim TM, Ozyilkan O, Smagina M, Leonova V, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E.J Thorac Oncol. 2025 Feb;20(2):203-218. doi: 10.1016/j.jtho.2024.10.012. Epub 2024 Oct 28.PMID: 39477187 Free article. Clinical Trial.

136. Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.

Koshkin VS, Danchaivijitr P, Bae WK, Semenov A, Ozyilkan O, Su YL, Arranz Arija JA, Tsujihata M, Bögemann M, Hendriks MP, Delgado SN, Rosenbaum E, Lopez KA, Bavle A, Liu CC, Imai K, Furka A.Eur Urol. 2025 Apr;87(4):390-395. doi: 10.1016/j.eururo.2024.11.012. Epub 2024 Dec 21.PMID: 39709248

Uluslararası alanda seçilmiş konferanslar

1. Title: Quality of life in colorectal cancer patients. Invited byEuropean School of Oncology (ESO) and presented at ESO course in Ankara, Turkey, 11/2000.

2. Title: Quality of life in cancee patients. Invited by European Society of Medical Oncology (ESMO) and presented at ESMO Workshop on PalliativeCare in Oncology in Bombay, India, 2/2003.

3. Title: Fatigue in cancer. Invited by EuropeanSociety of Medical Oncology (ESMO) and presented at ESMO Workshop on Palliative Care in Oncology in Bombay, India, 2/2003.

4. Title: Olive-oil consuption and cancer risk, Invited byThe First Regional Meeting of

Asian Pacific Organization for Cancer Prevention (APOCP) in Izmir, Turkey 10/2003

Bugüne kadar kanser hastalarına yönelik palyatif bakıma ne gibi katkılarda bulundunuz?

- MASCC'nin aktif bir üyesiyim.

- 2004 yılında İstanbul, Türkiye'de MASCC ile işbirliği içinde "Onkolojide Evde Bakım ve Palyatif Bakım" konulu bir kurs düzenledim.

- ESMO Palyatif Bakım Çalışma Grubu'nun kurucu üyesiyim.

- Avrupa, Asya ve Orta Doğu Kanser Konsorsiyumu'nda (MECC) palyatif bakımla ilgili birçok faaliyete başkanlık ettim ve katıldım.

- Hindistan'da (2003) ve Türkiye'de (2006) ESMO destekli Palyatif Bakım kursları düzenledim.

- 2007 yılında Gürcistan, Tiflis'te düzenlenen 1. Palyatif Kanser Bakımı Masterclass'ında Avrupa Onkoloji Okulu'nun öğretim üyesiydim.

- 2007 yılında Mısır, Kahire'de düzenlenen 1. EASO Klinik Onkoloji Masterclass'ında Euro-Arap Onkoloji Okulu'nun öğretim üyesiydim.

Uluslararası Kanser Destekleyici Bakım Birliği

Türk Tıbbi Onkoloji Derneği

Türk İç Hastalıkları Derneği

Çok çeşitli klinik ve translasyonel araştırma projelerinde yer aldım ve uluslararası sunumlar ile hakemli yayınlardan oluşan geniş bir listeye sahibim. Hasta bakımı ve akademik araştırmalarda aktif olarak yer alıyorum; bu kapsamda çok sayıda meme kanseri ve akciğer kanseri protokolünde kurumun Baş Araştırmacısı olarak görev yaptım. 2001 yılından itibaren Başkent Üniversitesi'nde Kanser Hizmetleri Klinik Direktörü olarak görev yaptım ve kurumdaki hastalara sunulan klinik bakımın güçlendirilmesi ve geliştirilmesine odaklandım.

Hasta odaklı araştırmalarla ilgileniyorum; özellikle tedaviye yanıtın ve tedavi etkinliğinin tahmin edilmesi ve onkolojide palyatif bakım konularına yoğunlaşıyorum.